These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 24957143)
21. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia. Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552 [TBL] [Abstract][Full Text] [Related]
22. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134 [TBL] [Abstract][Full Text] [Related]
24. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753 [TBL] [Abstract][Full Text] [Related]
25. Primary plasma cell leukemia in the era of new drugs: has something changed? Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304 [TBL] [Abstract][Full Text] [Related]
26. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study. Deng J; Qin X; Ma G; Shen X; Sun J; Zhao Y; Zhang Z; Sun Y; Jie G; Su L; Ma J; Tian W; Yang L; Wang Q; Huang H; Shi M; Ma Y; Gao W; Chen W Ann Hematol; 2024 Sep; 103(9):3691-3699. PubMed ID: 39073588 [TBL] [Abstract][Full Text] [Related]
27. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Ramsingh G; Mehan P; Luo J; Vij R; Morgensztern D Cancer; 2009 Dec; 115(24):5734-9. PubMed ID: 19877113 [TBL] [Abstract][Full Text] [Related]
28. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491 [TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
33. An update on biology, diagnosis and treatment of primary plasma cell leukemia. Musto P; Statuto T; Valvano L; Grieco V; Nozza F; Vona G; Bochicchio GB; La Rocca F; D'Auria F Expert Rev Hematol; 2019 Apr; 12(4):245-253. PubMed ID: 30905220 [TBL] [Abstract][Full Text] [Related]
34. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study. Guan J; Ma J; Chen B Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631 [TBL] [Abstract][Full Text] [Related]
35. How I treat plasma cell leukemia. van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533 [TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948 [TBL] [Abstract][Full Text] [Related]
37. Plasma cell leukemia: concepts and management. Liedtke M; Medeiros BC Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471 [TBL] [Abstract][Full Text] [Related]
38. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study. Wang H; Zhou H; Zhang Z; Geng C; Chen W Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277 [TBL] [Abstract][Full Text] [Related]
39. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A; Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060 [TBL] [Abstract][Full Text] [Related]
40. Primary plasma cell leukemia 2.0: advances in biology and clinical management. Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]